Preview

Научно-практическая ревматология

Расширенный поиск

Переносимость инфликсимаба у пациентов с ревматоидным артритом в реальной клинической практике

https://doi.org/10.14412/1995-4484-2020-31-36

Полный текст:

Аннотация

Широкий спектр генно-инженерных биологических препаратов, введенных в клиническую ревматологию за последние годы, обусловливает особый интерес к их переносимости. В статье представлены собственные данные авторов, а также обзор зарубежной литературы, посвященной данному вопросу.

Цель исследования — проанализировать переносимость инфликсимаба (ИНФ) у больных ревматоидным артритом (РА) в реальной клинической практике.

Материал и методы. В анализ было включено 135 больных РА, получавших ИНФ в комбинации с базисными противовоспалительными препаратами или в виде монотерапии.

Результаты и обсуждение. Общая переносимость ИНФ была удовлетворительной. Неблагоприятные реакции (НР) отмечались в 28,1% случаев, в том числе у 19 (14,1%) пациентов — серьезные НР, потребовавшие отмены препарата.

Заключение. Наилучшая переносимость отмечалась при использовании комбинации ИНФ и метотрексата. Авторы обращают внимание на необходимость врачебного осмотра перед каждым введением препарата.

Об авторах

Е. С. Аронова
ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой
Россия

Евгения Сергеевна Аронова

15522, Москва, Каширское шоссе, 34А



Г. В. Лукина
ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой; ГБУЗ г. Москвы «Московский клинический научнопрактический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы
Россия

15522, Москва, Каширское шоссе, 34А; 111123, Москва, шоссе Энтузиастов, 86



Я. А. Сигидин
ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой
Россия

15522, Москва, Каширское шоссе, 34А



Список литературы

1. Сигидин ЯА, Лукина ГВ. Биологическая терапия в ревматологии. 2-е изд., доп. Москва: Практическая медицина; 2009. 64 с.

2. Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. JRheumatol. 2010;37(5):928-31. doi: 10.3899/jrheum.091107

3. Galloway JB, Hyrich KL, Mercer LK, et al; BSRBR Control Centre Consortium; on behalf of the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124-31. doi: 10.1093/rheumatology/keq242

4. Leombruno J. The challenges of quantifying the risk of serious infection with tumor necrosis factor antagonist therapy. J Rheumatol. 2010 May;37(5):887-9. doi: 10.3899/jrheum.100251

5. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692

6. Hongxing Liao, Zhixiong Zhong, Zhanliang Liu, Xuenong Zou. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20:161-8. doi: 10.1111/1756-185X.12970

7. Kharbanda P, Dagaonkar R, Balakrishnan C, Udwadia ZF. Tumor necrosis factor-alpha blocker induced tuberculosis. J Rheumatol. 2010 Jul;37(7):1542; author reply 1543. doi: 10.3899/jrheum.100058

8. Girlanda S, Mantegani P, Baldissera E, et al. ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment. Clin Rheumatol. 2010 Oct;29(10):1135-41. doi: 10.1007/s10067-010-1532-1. Epub 2010 Jul 20.

9. Reenaers C, Belaiche J, Louis E. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflamm Bowel Dis. 2010 Aug;16(8):1271-2. doi: 10.1002/ibd.21162

10. Malaviya AN, Kapoor S, Garg S, Rawat R. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India — followup report. J Rheumatol. 2010 Jan;37(1):209. doi: 10.3899/jrheum.090854

11. Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Res Ther. 2010;12:103. doi: 10.1186/ar2899

12. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011 Nov;90(6):359-71. doi: 10.1097/MD.0b013e3182380a76

13. Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015 Sep 28;21(36):10274-89. doi: 10.3748/wjg.v21.i36.10274

14. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021-9. doi: 10.1007/s10067-010-1523-2

15. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. doi: 10.1002/acr.20130

16. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-a inhibitors and chronic hepatitis C: A comprehensive literature review. Clin Gastroenterol Hepatol. 2013 May;11(5):558-64.

17. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010 Mar;6(3):165-74. doi: 10.1038/nrrheum.2009.279. Epub 2010 Feb 9.

18. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum. 2010;62(11):3191-5. doi: 10.1002/art.27687

19. Summut L, Wallis D, Holroyd C. Progressive multifocal leukoen-cephalopathy associated with infliximab. JR Coll Physicians (Edinb). 2016 Sep;46(3):163-5. doi: 10.4997/JRCPE.2016.305

20. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010 Aug;62(8):2517-24. doi: 10.1002/art.27511

21. Onel KB, Onel K. Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res (Hoboken). 2010 Apr 21;62(7):1024-8. doi: 10.1002/acr.20228

22. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010 Feb;69(2):400-8. doi: 10.1136/ard.2009.117762. Epub 2009 Oct 14.

23. Chen Y, Friedman M, Liu G, et al. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78-88. doi: 10.1016/j.cyto.2016.09.013

24. Raaschou P, Simard JF, Hagelberg CA, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016 Jan 28;352:i262. doi: 10.1136/bmj.i262

25. Amari W, Zeringue AL, McDonald JR, et al. Risk of nonmelanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1431-9. doi: 10.1093/rheumatology/ker113

26. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012 Jun;71(6):869-74. doi: 10.1136/annrheumdis-2011-200622

27. Farshid G, Prowse P, True B. Epithelioid myxofibrosarcoma developing at the injection site of Adalimumab therapy for psoriatic synovitis. Eur J Rheumatol. 2018 Jul;5(2):131-4. doi: 10.5152/eur-jrheum.2017.17083

28. Dixon WG, Watson KD, Lunt M, et al; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129

29. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010 Jan 8;12(1):R5. doi: 10.1186/ar2904

30. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003

31. Santos RC, Figuiredo VN, Martins LC, et al. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc Med Bras. 2012;58(6):698-702. doi: 10.1590/S0104-42302012000600015

32. Miehsler W, Novacek G, Wenzl H, et al. Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4: 22156. doi: 10.1016/j.crohns.2009.12.001

33. Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010 Jun;62(6):764-9. doi: 10.1002/acr.20037

34. Cancelliere N, Barranco P, Vidaurrazaga C, et al. Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept. JInvestig Alergol Clin Immunol. 2011;21:248-9.

35. Tugnet N, Youssef A, Whallett AJ. Wells’ syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford). 2012;51:195-6. doi: 10.1093/rheumatology/ker322

36. Poliak N, Orange JS, Pawel BR, Weiss PF. Eosinophilic fasciitis mimicking angioedema and treatment response to infliximab in a pediatric patient. Ann Allergy Asthma Immunol. 2011;106:444-5. doi: 10.1016/j.anai.2011.01.021

37. Alshekaili J, Li C, Cook MC. Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment. Rheumatology (Oxford). 2010 May;49(5):891-7. doi: 10.1093/rheumatology/keq018. Epub 2010 Feb 23.

38. Saraceno R, Specchio F, Torres T, et al. The significance of the development of antinuclear antibodies during infliximab treatment. J Am Acad Dermatol. 2013 Aug;69(2):314. doi: 10.1016/j.jaad.2013.03.020

39. Vaz JLP, Andrade CAF, Pereira AC, et al. Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol. 2013;53(4):358-64. doi: 10.1016/S2255-5021(13)70049-X

40. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011 May;50(5):619-25. doi: 10.1111/j.1365-4632.2011.04871.x

41. Sokolove J, Strand V, Greenberg JD, et al; on behalf of the CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep;69(9):1612-7. doi: 10.1136/ard.2009.112136

42. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013 May;11(5):558-64.e3. doi: 10.1016/j.cgh.2012.12.025

43. Goujon C, Dahel K, Berard F, et al. Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol. 2010 Aug;63(2):e43-4. doi: 10.1016/j.jaad.2009.02.029

44. Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with crohn’s disease with no relapse after switching to adalimumab. BioDrugs. 2010 Dec 14;24 Suppl 1:25-7. doi: 10.2165/11586210-000000000-00000

45. Kinnunen U, Farkkila M, Makisalo H. A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. J Crohn’s Colitis. 2012 Jul;6(6):724-7. doi: 10.1016/j.crohns.2012.02.004

46. Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463. doi: 10.1155/2014/956463

47. Aasly JO. Bilateral Optic Neuritis Associated with the Use of Infliximab. Case Rep Ophthalmol Med. 2011;2011:232986. doi: 10.1155/2011/232986

48. Faillace C, de Almeida JR, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013 Apr;33(4):1101-3. doi: 10.1007/s00296-011-2316-x

49. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new «class effect» paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010 Feb;39(4):313-9. doi: 10.1016/j.semarthrit.2008.11.003

50. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010 Jul;146(7):780-4. doi: 10.1001/archdermatol.2010.142

51. Dipasquale V, Gramaglia SMC, Catena MA, Romano C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J Clin Pharm Ther. 2018;43(1):107-9. doi: 10.1111/jcpt.12586

52. Patwala K, Crump N, De Cruz P. Guillain-Barre syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity. Case Rep. 2017;2017:bcr-2017-219481. doi: 10.1136/bcr-2017-219481

53. Singh JA, Wells GA, Christensen R, et al Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):Art. No. CD008794. doi: 10.1002/14651858.CD008794

54. Singh JA, Wells GA, Christensen R, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016;(5). doi: 10.1002/14651858.CD012183

55. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20. doi: 10.1136/annrheumdis-2012-203090

56. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:article number 82. doi: 10.1186/s13075-016-0981-6

57. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355-63. doi: 10.1136/annrheumdis-2015-208786

58. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12. doi: 10.1136/annrheumdis-2012-203091

59. Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. doi: 10.1186/s13075-016-0930-4

60. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346-54. doi: 10.1136/annrheumdis-2015-208783

61. Каратеев ДЕ, Мазуров ВИ, Зонова ЕВ и др. Сравнительная эффективность и безопасность биоаналога инфликсимаба (BCD-055) и оригинального инфликсимаба у пациентов с ан-килозирующим спондилитом (результаты международных многоцентровых рандомизированных двойных слепых клинических исследований I и III фазы). Современная ревматология. 2017;11(3):14-25

62. Лила АМ, Мазуров ВИ, Зонова ЕВ и др. Сравнительная оценка долгосрочной эффективности и безопасности биоаналога инфликсимаба BCD-055 и референтного инфликсимаба у пациентов с анкилозирующим спондилитом: результаты международного многоцентрового рандомизированного двойного слепого клинического исследования III фазы ASART-2. Научно-практическая ревматология. 2018;56(3):293-301 doi: 10.14412/1995-4484-2018-293-301


Для цитирования:


Аронова Е.С., Лукина Г.В., Сигидин Я.А. Переносимость инфликсимаба у пациентов с ревматоидным артритом в реальной клинической практике. Научно-практическая ревматология. 2020;58(1):31-36. https://doi.org/10.14412/1995-4484-2020-31-36

For citation:


Aronova E.S., Lukina G.V., Sigidin Y.A. Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice. Rheumatology Science and Practice. 2020;58(1):31-36. (In Russ.) https://doi.org/10.14412/1995-4484-2020-31-36

Просмотров: 201


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)